オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - oxaliplatin, quantity: 200 mg - injection, concentrated - excipient ingredients: water for injections - oxaliplatin is indicated for adjuvant treatment of stage iii (duke?s c) colon cancer, in combination with fluoropyrimidine agent.,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer.,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer.,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for: the treatment of patients with advanced oesophagogastric cancer

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - oxaliplatin, quantity: 100 mg - injection, concentrated - excipient ingredients: water for injections - oxaliplatin is indicated for adjuvant treatment of stage iii (duke?s c) colon cancer, in combination with fluoropyrimidine agent.,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer.,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer.,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for: the treatment of patients with advanced oesophagogastric cancer

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - oxaliplatin, quantity: 50 mg - injection, concentrated - excipient ingredients: water for injections - oxaliplatin is indicated for adjuvant treatment of stage iii (duke?s c) colon cancer, in combination with fluoropyrimidine agent.,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer.,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer.,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for: the treatment of patients with advanced oesophagogastric cancer

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - oxaliplatin, quantity: 100 mg - injection, intravenous infusion - excipient ingredients: tartaric acid; water for injections; sodium hydroxide - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour. - treatment of advanced colorectal cancer.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - oxaliplatin, quantity: 50 mg - injection, intravenous infusion - excipient ingredients: water for injections; sodium hydroxide; tartaric acid - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour. - treatment of advanced colorectal cancer.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

alvogen inc. - oxaliplatin (unii: 04zr38536j) (oxaliplatin - unii:04zr38536j) - oxaliplatin 5 mg in 1 ml - oxaliplatin injection, usp used in combination with infusional 5-fluorouracil/leucovorin, is indicated for: - adjuvant treatment of stage iii colon cancer in patients who have undergone complete resection of the primary tumor. - treatment of advanced colorectal cancer. oxaliplatin injection, usp should not be administered to patients with a history of known allergy to oxaliplatin injection, usp or other platinum compounds [see warnings and precautions (5.1)] . pregnancy category d based on direct interaction with dna, oxaliplatin injection, usp may cause fetal harm when administered to a pregnant woman. there are no adequate and well-controlled studies of oxaliplatin injection, usp in pregnant women. reproductive toxicity studies in rats demonstrated adverse effects on fertility and embryo-fetal development at maternal doses that were below the recommended human dose based on body surface area. if this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

breckenridge pharmaceutical, inc. - oxaliplatin (unii: 04zr38536j) (oxaliplatin - unii:04zr38536j) - oxaliplatin 50 mg in 10 ml - oxaliplatin injection, usp used in combination with infusional 5-fluorouracil/leucovorin, is indicated for: - adjuvant treatment of stage iii colon cancer in patients who have undergone complete resection of the primary tumor. - treatment of advanced colorectal cancer. oxaliplatin injection, usp should not be administered to patients with a history of known allergy to oxaliplatin injection, usp or other platinum compounds [see warnings and precautions (5.1)] . pregnancy category d based on direct interaction with dna, oxaliplatin injection, usp may cause fetal harm when administered to a pregnant woman. there are no adequate and well-controlled studies of oxaliplatin injection, usp in pregnant women. reproductive toxicity studies in rats demonstrated adverse effects on fertility and embryo-fetal development at maternal doses that were below the recommended human dose based on body surface area. if this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

app pharmaceuticals, llc - oxaliplatin (unii: 04zr38536j) (oxaliplatin - unii:04zr38536j) - oxaliplatin 50 mg in 10 ml - oxaliplatin, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for - adjuvant treatment of stage iii colon cancer in patients who have undergone complete resection of the primary tumor. - treatment of advanced colorectal cancer. oxaliplatin should not be administered to patients with a history of known allergy to oxaliplatin or other platinum compounds [see warnings and precautions (5.1)] . pregnancy category d based on direct interaction with dna, oxaliplatin may cause fetal harm when administered to a pregnant woman. there are no adequate and well-controlled studies of oxaliplatin in pregnant women. reproductive toxicity studies in rats demonstrated adverse effects on fertility and embryo-fetal development at maternal doses that were below the recommended human dose based on body surface area. if this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. women of childbeari

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - oxaliplatin, quantity: 100 mg - injection, concentrated - excipient ingredients: water for injections; lactose monohydrate - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour; treatment of advanced colorectal cancer.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - oxaliplatin, quantity: 50 mg - injection, concentrated - excipient ingredients: water for injections; lactose monohydrate - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour; treatment of advanced colorectal cancer.